CG
NVLN

Cutler Group’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Cutler Group’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2,700
Closed -$1K – 7629
2016
Q4 		$1K Buy
+2,700
New +$23.9K ﹤0.01% 6289

Other funds holding NVLN

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cutler Group's NVLN Position: Q2 2017 in Review

Cutler Group sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q2 2017, closing a stake of 15,119 shares — an estimated $162K sold.

Cutler Group first reported a position in NVLN in Q4 2016 and held it in 2 quarters. The position peaked at $162K in Q1 2017. 76 funds tracked by Wall St. Rank hold NVLN as of Q2 2017.

  • Cutler Group reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q2 2017 after selling out during the quarter.
  • Cutler Group sold 15,119 Novelion Therapeutics Inc. Common Shares shares in Q2 2017, an estimated $162K.
  • Cutler Group first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 2 quarters.
  • Cutler Group's Novelion Therapeutics Inc. Common Shares position peaked at $162K in Q1 2017.
  • 76 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q2 2017.

Based on Cutler Group's 13F filing for Q2 2017, filed 11 Jul 2017.